Anavo Therapeutics is a biotechnology company focused on the development of allosteric modulators for phosphatases, aiming to create a pipeline of novel therapeutics for various diseases.

Debora Dumont

Nico Vandervelpen

Anavo Therapeutics

Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.

Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.

… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.

… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. 

… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.

Bioqube Ventures

Fellowship opportunity! Do you have a scientific background, are you passionate about developing therapeutics and eager to learn more about what makes venture capital tick in biotech? Then this 6-month Fellowship program at Bioqube might be the right fit for you! Find out more in the description below ⤵️ #vc #biotech #fellowship

Exciting update from our portfolio company @Bicara Therapeutics at @ESMO !

Welcome Krishna Polu ! What a great addition to our Bioqube Ventures team! Proud to be part of this family!

Exciting update from Bioqube portfolio company Bicara Therapeutics, congratulations to the team on unveiling their manuscript. Read all about it below. #aacr23 #BFFI
https://lnkd.in/eMAwSuya

Bioqube Ventures is pleased to welcome Bicara Therapeutics to our portfolio, a clinical-stage biotech advancing its lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers.

https://lnkd.in/efJAtW9Q

Metric
Company Name	Anavo Therapeutics
Symbol
MSH ID	COM:BIOQUBEVENTURES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	BE
Stage	Seed
Employee Count	13
Website	bioqubeventures.com
LinkedIn	bioqube-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	145
Web Traffic Growth	-0.86
Valuation
Raised Capital	9.36M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BIOQUBEVENTURES

Anavo Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue